Quantcast

Latest Juvenile idiopathic arthritis Stories

2009-03-26 08:20:00

Twenty Percent of Surveyed MCO Pharmacy Directors Say They Will Alter Reimbursement of TNF-alpha Inhibitors for Juvenile Idiopathic Arthritis and Pediatric Crohn's Disease, According to a New Report from Decision Resources WALTHAM, Mass., March 26 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that 30 percent of surveyed rheumatologists have altered their prescription patterns for juvenile idiopathic...

2009-02-26 17:01:50

Arthritis, common among those having heart disease, may be a barrier for patients to getting needed physical activity, a U.S. government study says. A study by the Centers for Disease Control and Prevention said adults with both heart disease and arthritis are significantly more likely to be physically inactive than those with heart disease alone. The study, published in the Morbidity and Mortality Weekly Report, said approximately 57 percent of adults with heart disease have arthritis. In...

2008-12-04 00:30:00

NUTLEY, N.J., Dec. 4 /PRNewswire/ -- Roche today announced that the U.S. Food and Drug Administration (FDA) has provided further guidance on the requirements for the Biologics License Application (BLA) for ACTEMRA(R) (tocilizumab), the first interleukin-6 (IL-6) receptor-inhibiting monoclonal antibody studied for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA). As a result of the FDA's evolving Risk Evaluation and Mitigation Strategy (REMS)...

2008-10-28 00:00:08

Bristol-Myers Squibb Company (NYSE: BMY) today announced at the American College of Rheumatology (ACR) Annual Scientific Meeting in San Francisco results from a 10-month study which showed that ORENCIA(R) (abatacept), compared to placebo, significantly improved multiple aspects of health-related quality of life (HRQoL): physical and psychosocial well being, pain and sleep quality in juvenile idiopathic arthritis (JIA) patients between the ages 6 and 17 years. These improvements with ORENCIA...

2008-10-25 21:00:11

NUTLEY, N.J., Oct. 25 /PRNewswire/ -- One-year data from a two-year Phase III study demonstrated that ACTEMRA(R) (tocilizumab) significantly inhibited the progression of structural joint damage in patients with rheumatoid arthritis (RA). Late-breaking results from the LITHE study will be featured as an oral presentation during the American College of Rheumatology (ACR) Annual Scientific Meeting (October 24-28) in San Francisco. Fourteen additional abstracts, which evaluate ACTEMRA, a novel...

2008-10-25 21:00:11

NUTLEY, N.J., Oct. 25 /PRNewswire/ -- Data from two Phase III studies showed that patients who suffer from the debilitating and painful effects of rheumatoid arthritis (RA) achieved significant improvements in signs and symptoms when treated with ACTEMRA(R) (tocilizumab) alone or in combination with methotrexate compared with methotrexate alone. The final results of both studies will be presented as oral presentations, along with 13 other abstracts which evaluate ACTEMRA in patients with...

2008-10-20 09:00:09

NUTLEY, N.J., Oct. 20 /PRNewswire/ -- Roche today announced that a total of 15 abstracts involving its investigational rheumatoid arthritis (RA) treatment ACTEMRA(R) (tocilizumab) have been accepted for presentation at the 2008 American College of Rheumatology (ACR) Annual Scientific Meeting, which will take place October 24-29 in San Francisco. These studies evaluate ACTEMRA, a novel treatment targeting interleukin-6 (IL-6) receptors, in patients with moderately to severely active RA....

2008-09-18 12:00:11

NUTLEY, N.J., Sept. 18 /PRNewswire/ -- Roche today announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter for the Biologics License Application (BLA) for ACTEMRA(R) (tocilizumab), the first interleukin-6 (IL-6) receptor-inhibiting monoclonal antibody studied for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA). The FDA has not requested any new clinical studies surrounding the efficacy or safety of...

2008-09-16 06:00:10

NORWALK, Conn., Sept. 16 /PRNewswire/ -- Arthritis afflicts half of Americans age 65 and older, according to the U.S. National Institutes of Health. Arthritis causes deterioration within the joints that serve as cushion between bones. The cartilage covering the end of the bone breaks down, resulting in difficulty moving the joint. Symptoms include joint pain, stiffness and swelling. Arthritis, as a result, disables more Americans than heart disease and stroke, according to government...

2008-08-28 03:00:19

By Taghdiri, Celia Many people are shocked to learn that arthritis isn't just "an old person's disease." The reality is about 300,000 U.S. children, or one in 250, have joint inflammation that causes pain, redness, heat and swelling. Juvenile arthritis occurs before age 16. The most common is juvenile idiopathic arthritis (JIA). Idiopathic means arising from an unknown cause. Targeting the body's joints, JIA is more frequent in girls and occurs generally from one to three years of age, and...


Word of the Day
Cthulhu
  • A gigantic fictional humanoid alien god being described with a head resembling an octopus and dragon wings and claws, around whom an insane cult developed.
  • Pertaining to the mythos of Cthulhu and additional otherworldly beings created by H. P. Lovecraft or inspired by his writings and imitators.
This word was invented in 1926 by H.P. Lovecraft for his short story, 'The Call of Cthulhu.' 'Cthulhu' may be based on the word 'chthonic,' which in Greek mythology refers to the underworld.
Related